The Latest Breaking News from MHRA

Two geneticists explain the groundbreaking CRISPR-based therapies approved for sickle-cell disease and β-thalassaemia, and other genetic therapeutics in development, including base-editing and prime-editing.

Given enhanced healthcare spending, the growing frequency of chronic diseases, government support, and rapid digital transformation, the biotech industry appears to have favorable prospects. Therefore, fundamentally strong biotech stocks Vertex Pharmaceuticals (VRTX), Innoviva (INVA), and Acorda Therapeutics, Inc. (ACOR) could be ideal additions to your portfolio this week. Read more….

U.K. regulators have approved the use of a CRISPR therapy called Casgevy to treat two inherited blood disorders. But what is it and how does it work?

Using the gene editing tool CRISPR, the new therapy promises a cure for those with sickle cell anemia and beta thalassemia, but cost could be a barrier to care.

The treatment is the first to be licensed using the gene-editing tool known as Crispr, for which its inventors were awarded the Nobel prize in 2020

The treatment is the first to be licensed using the gene-editing tool known as Crispr, for which its inventors were awarded the Nobel prize in 2020.

Anastrozole has the potential to reduce the risk of breast cancer by almost 50% for many postmenopausal women at risk, here's what you need to know

Obese and overweight adults could have access to Tirzepatide – also known as Mounjaro – if it receives further approval.

Exclusive: Regulator extends part suspension of licence to July 2024 after IT blunder led to incorrect dosage of cancer treatment

The boom in sales of mushroom products has led to many claims for their wellbeing and curative properties, but is there any scientific evidence to back them up?

Medicines regulator seizes 369 potentially fake devices amid surge in demand